A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, comprising approximately 75–80% of all lung cancers. Gemcitabine is an approved chemotherapy drug for NSCLC. The objective of this study was to develop a novel strategy to improve the therapeutic efficacy of Gemcitabine for N...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qing, Zhang, Yang, Li, Ke, Wang, Haiyu, Li, Huizhong, Zheng, Junnian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466375/
https://www.ncbi.nlm.nih.gov/pubmed/26066322
http://dx.doi.org/10.1371/journal.pone.0129865

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4466375/
https://www.ncbi.nlm.nih.gov/pubmed/26066322
http://dx.doi.org/10.1371/journal.pone.0129865

Ejemplares similares